Roche and Genen­tech re­searchers plot $53M dis­cov­ery quest aimed at spark­ing a 'Holy moly' piv­ot in neu­ro R&D

Roche and Genen­tech have com­mit­ted $53 mil­lion to back a 10-year quest aimed at go­ing back to the draw­ing board to use new tech­nol­o­gy and fresh sci­en­tif­ic in­sights to gen­er­ate a pipeline of drugs for neu­ro­log­i­cal dis­eases.

Re­searchers from both Roche and its big South San Fran­cis­co hub — mix­ing teams from gRED and pRED this time — will mix it up with the sci­en­tists drawn to­geth­er for the Weill Neu­ro­hub — formed in 2019 as a joint re­search part­ner­ship in­volv­ing UCSF, Berke­ley and the Uni­ver­si­ty of Wash­ing­ton — in an ex­plo­ration of the field to de­vel­op new ther­a­pies for some of the tough­est dis­eases in drug R&D: Alzheimer’s, Parkin­son’s, Hunt­ing­ton’s, ALS and autism.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.